EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Low Blood Pressure and the Effect of Empagliflozin in Acute Heart Failure: An EMPULSE Analysis

João Pedro Ferreira iD, Francisco Vasques-Nóvoa, Christiane E Angermann, Jan Biegus, Sean P Collins, Mikhail Kosiborod, Michael E Nassif, Mitchell A Psotka, Jasper Tromp, Robert J Mentz, Piotr Ponikowski, John R Teerlink und 1 weitere

European Journal of Heart Failure · 01.04.2025 · 27 (4) · 671-680

DOI: 10.1002/ejhf.3626 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Heart Failure, online erschienen am 20.02.2025. Verfasst von João Pedro Ferreira und 12 weiteren Autor:innen. Beteiligte Einrichtung: Université de Lorraine, Inserm, Centre d'Investigations Cliniques, - Plurithématique 14-33, Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT (Cardiovascular…. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Blood Pressure, Glucosides, Heart Failure. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Boehringer Ingelheim, Boehringer Ingelheim España.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Empagliflozin improves outcomes in acute heart failure (AHF). Patients with AHF and low blood pressure (BP) have poor prognosis. Whether empagliflozin is effective and safe in patients with AHF and low BP is currently unknown. The aim of this study was to assess the efficacy and safety of empagliflozin (vs. placebo) in patients with low BP – either systolic BP (SBP) <110 mmHg or diastolic BP (DBP) <70 mmHg – at randomization. Methods and results EMPULSE included 530 patients with AHF followed for 90 days. The primary outcome was a hierarchical composite of all-cause mortality, HF events, and Kansas City Cardiomyopathy Questionnaire total symptom score changes at 90 days tested using the win ratio (WR). Patients were required to have SBP ≥100 mmHg for randomization. A total of 131 (25%) patients had SBP <110 mmHg and 190 (36%) DBP <70 mmHg. In placebo, low BP was associated with more clinical and adverse events. Compared to placebo, BP changes with empagliflozin were of small magnitude (−2 to 2 mmHg), not reaching statistical significance. Patients presenting with low BP increased their BP, on average, throughout the 90-day follow-up, regardless of treatment group. Empagliflozin (vs. placebo) improved clinical outcomes regardless of BP at randomization, potentially with a larger magnitude of effect in patients presenting with low DBP at randomization: primary outcome WR = 1.48, 95% confidence interval (CI) 1.15–1.90, p = 0.0025; WR = 1.23, 95% CI 0.94–1.60 in DBP ≥70 mmHg and WR = 2.11, 95% CI 1.46–3.04 in DBP < 70 mmHg (interaction p = 0.02).

Conclusions

Patients admitted for AHF with low BP had a higher risk of clinical events. Empagliflozin did not lower BP more than placebo and was effective and safe irrespective of BP. Empagliflozin should be considered for the treatment of AHF patients even when presenting with low BP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Benzhydryl CompoundsBlood PressureGlucosidesHeart FailureHypotensionSodium-Glucose Transporter 2 InhibitorsAgedFemaleHumansMaleMiddle AgedAcute DiseaseDouble-Blind MethodFollow-Up StudiesTreatment Outcome

Stichwörter der Autor:innen

Acute heart failureEmpagliflozinLow blood pressure

Substanzen

Benzhydryl CompoundsempagliflozinGlucosidesSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Université de Lorraine, Inserm, Centre d'Investigations Cliniques, - Plurithématique 14-33, Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.
  • Cardiovascular R&D Centre (UnIC); Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal.
  • Heart Failure Clinic, Unidades Locais de Saúde de Gaia/Espinho & São João, Porto, Portugal.
  • Comprehensive Heart Failure Centre, University & University Hospital of Würzburg, Würzburg, Germany.
  • Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland.
  • Department of Emergency Medicine, Vanderbilt University Medical Center and Geriatric Research and Education Clinical Care, Tennessee Valley Healthcare Facility VA Medical Center, Nashville, TN, USA.

ORCID-Profile: João Pedro Ferreira

Förderung

  • Boehringer Ingelheim
  • Boehringer Ingelheim España

Zitieren

APA

Ferreira, J. P., Vasques-Nóvoa, F., Angermann, C. E., Biegus, J., Collins, S. P., Kosiborod, M., Nassif, M. E., Psotka, M. A., Tromp, J., Mentz, R. J., Ponikowski, P., Teerlink, J. R., & Voors, A. A. (2025). Low Blood Pressure and the Effect of Empagliflozin in Acute Heart Failure: An EMPULSE Analysis. European Journal of Heart Failure, 27(4), 671-680. https://doi.org/10.1002/ejhf.3626

Vancouver

Ferreira JP, Vasques-Nóvoa F, Angermann CE, Biegus J, Collins SP, Kosiborod M, et al. Low Blood Pressure and the Effect of Empagliflozin in Acute Heart Failure: An EMPULSE Analysis. European Journal of Heart Failure. 2025;27(4):671-680. doi:10.1002/ejhf.3626

BibTeX
@article{Ferreira2025,
  author = {Ferreira, João Pedro and Vasques-Nóvoa, Francisco and Angermann, Christiane E and Biegus, Jan and Collins, Sean P and Kosiborod, Mikhail and Nassif, Michael E and Psotka, Mitchell A and Tromp, Jasper and Mentz, Robert J and Ponikowski, Piotr and Teerlink, John R and Voors, Adriaan A},
  title = {Low Blood Pressure and the Effect of Empagliflozin in Acute Heart Failure: An EMPULSE Analysis},
  journal = {European Journal of Heart Failure},
  year = {2025},
  volume = {27},
  number = {4},
  pages = {671--680},
  doi = {10.1002/ejhf.3626}
}
Kostenlos starten →